http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102122903-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-308 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-689 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-742 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-689 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6851 |
| filingDate | 2020-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102122903-B1 |
| titleOfInvention | Nanovesicles derived from Blautia bacteria and Use thereof |
| abstract | The present invention relates to a bacterial-derived vesicle derived from the genus Blautia, and uses thereof, in the clinical sample of colorectal cancer, liver cancer, pancreatic cancer, bile duct cancer, ovarian cancer, bladder cancer, myocardial infarction, atrial fibrillation and angina pectoris compared to normal humans. The vesicles were significantly reduced, and when the vesicles isolated from the strain were administered, it was experimentally confirmed that the inflammatory mediator secretion was significantly suppressed by pathogenic vesicles such as E. coli-derived vesicles. Bacterial-derived vesicles include colon cancer, liver cancer, pancreatic cancer, bile duct cancer, ovarian cancer, bladder cancer, myocardial infarction, atrial fibrillation, or angina pectoris, and colon disease, liver disease, pancreatic disease, bile duct cancer, ovarian cancer, bladder cancer, myocardial infarction , Atrial fibrillation, angina pectoris, or graft-versus-host disease may be useful for the purpose of developing a composition for prevention, improvement or treatment. |
| priorityDate | 2018-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 165.